This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Open-Label study of bevacizumab (Avastin�) and tax...
Clinical trial

Open-Label study of bevacizumab (Avastin�) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer

Read time: 1 mins
Last updated:1st Oct 2009
Tolerability and safety profile of bevacizumab when combined with weekly paclitaxel as first line treatment of metastatic triple negative breast cancer.
Category Value
Study start date 2009-10-01

View full details